BR112017007782A2 - agentes imunorreguladores - Google Patents
agentes imunorreguladoresInfo
- Publication number
- BR112017007782A2 BR112017007782A2 BR112017007782A BR112017007782A BR112017007782A2 BR 112017007782 A2 BR112017007782 A2 BR 112017007782A2 BR 112017007782 A BR112017007782 A BR 112017007782A BR 112017007782 A BR112017007782 A BR 112017007782A BR 112017007782 A2 BR112017007782 A2 BR 112017007782A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- immunoregulatory agents
- dioxigenase
- indoleamine
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
- C07C211/45—Monoamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/10—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/59—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/74—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/50—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462075678P | 2014-11-05 | 2014-11-05 | |
PCT/US2015/059316 WO2016073774A2 (en) | 2014-11-05 | 2015-11-05 | Immunoregulatory agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017007782A2 true BR112017007782A2 (pt) | 2018-01-16 |
Family
ID=55910037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017007782A BR112017007782A2 (pt) | 2014-11-05 | 2015-11-05 | agentes imunorreguladores |
Country Status (23)
Country | Link |
---|---|
US (3) | US20180325889A1 (pt) |
EP (1) | EP3215142B1 (pt) |
JP (1) | JP6762299B2 (pt) |
KR (1) | KR102647639B1 (pt) |
CN (1) | CN106999450B (pt) |
AR (1) | AR102537A1 (pt) |
AU (1) | AU2015342944A1 (pt) |
BR (1) | BR112017007782A2 (pt) |
CA (1) | CA2964297A1 (pt) |
CL (1) | CL2017001126A1 (pt) |
CO (1) | CO2017005218A2 (pt) |
EA (1) | EA201790998A1 (pt) |
ES (1) | ES2867748T3 (pt) |
IL (1) | IL252010A0 (pt) |
MA (2) | MA44549A1 (pt) |
MX (1) | MX2017005729A (pt) |
PE (1) | PE20171623A1 (pt) |
PH (1) | PH12017500604A1 (pt) |
SG (1) | SG11201702827VA (pt) |
TN (1) | TN2017000165A1 (pt) |
TW (1) | TW201630866A (pt) |
UY (1) | UY36391A (pt) |
WO (1) | WO2016073774A2 (pt) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
JP2017525753A (ja) | 2014-06-06 | 2017-09-07 | フレクサス・バイオサイエンシーズ・インコーポレイテッドFlexus Biosciences, Inc. | 免疫調節剤 |
AR102537A1 (es) | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | Agentes inmunomoduladores |
UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
JP2017538678A (ja) | 2014-11-05 | 2017-12-28 | フレクサス・バイオサイエンシーズ・インコーポレイテッドFlexus Biosciences, Inc. | 免疫調節剤 |
CN109562137A (zh) | 2015-09-01 | 2019-04-02 | 第波生物公司 | 用于治疗与异常炎性反应有关的病况的方法和组合物 |
WO2017192840A1 (en) | 2016-05-04 | 2017-11-09 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
EP3452030A4 (en) * | 2016-05-04 | 2019-11-13 | Bristol-Myers Squibb Company | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE AND METHOD FOR THEIR USE |
JP2019516687A (ja) | 2016-05-04 | 2019-06-20 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | インドールアミン2,3−ジオキシゲナーゼ阻害剤およびその使用方法 |
JP2019516681A (ja) | 2016-05-04 | 2019-06-20 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | インドールアミン2,3−ジオキシゲナーゼ阻害剤およびその使用方法 |
EP3452450A1 (en) | 2016-05-04 | 2019-03-13 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
JOP20170131B1 (ar) * | 2016-06-10 | 2021-08-17 | Lilly Co Eli | مركبات 1-تيترا هيدروبيرانييل كاربونيل -2،3-ديهيدرو -1 h- اندول لعلاج السرطان |
CN107674029A (zh) * | 2016-08-02 | 2018-02-09 | 上海迪诺医药科技有限公司 | 多环化合物、其药物组合物及应用 |
CN107674013B (zh) * | 2016-08-02 | 2022-05-24 | 上海迪诺医药科技有限公司 | 多环化合物、其制备方法、药物组合物及应用 |
US11046682B2 (en) | 2016-08-23 | 2021-06-29 | Beijing Innocare Pharma Tech Co., Ltd. | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof |
KR20190040990A (ko) * | 2016-08-26 | 2019-04-19 | 브리스톨-마이어스 스큅 컴퍼니 | 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법 |
CN109952300B (zh) | 2016-09-24 | 2022-01-18 | 百济神州有限公司 | 5或8-取代的咪唑并[1,5-a]吡啶 |
EP3515486A4 (en) * | 2016-09-26 | 2020-05-20 | Advantagene, Inc. | METHODS OF TREATING TIM-3 LEVEL INCREASE |
IL292677A (en) | 2016-12-22 | 2022-07-01 | Calithera Biosciences Inc | Preparations and methods for inhibiting arginase activity |
JP2020506895A (ja) * | 2017-01-17 | 2020-03-05 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | インドールアミン2,3−ジオキシゲナーゼおよび/またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物 |
WO2018209049A1 (en) | 2017-05-12 | 2018-11-15 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
BR112019027156A2 (pt) | 2017-06-30 | 2020-06-30 | Bristol-Myers Squibb Company | compostos de quinolinilciclo-hexilpropanamida substituídos e métodos melhorados para sua preparação |
EP3644993B1 (en) * | 2017-06-30 | 2023-08-02 | Bristol-Myers Squibb Company | Amorphous and crystalline forms of ido inhibitors |
EP3686196A4 (en) * | 2017-09-20 | 2021-03-31 | Hangzhou Innogate Pharma Co., Ltd. | POLYCYCLIC CONNECTION AS IDO INHIBITOR AND / OR IDO HDAC DOUBLE INHIBITOR |
CN111386117A (zh) | 2017-09-29 | 2020-07-07 | 百时美施贵宝公司 | 治疗癌症的组合物和方法 |
US11111232B2 (en) | 2017-10-09 | 2021-09-07 | Merck Sharp & Dohme Corp. | Substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
EP3694502B1 (en) | 2017-10-09 | 2023-08-02 | Merck Sharp & Dohme LLC | Novel substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
WO2019074824A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE |
US11649212B2 (en) | 2017-10-09 | 2023-05-16 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11180497B2 (en) | 2017-10-18 | 2021-11-23 | Angex Pharmaceutical, Inc. | Cyclic compounds as immunomodulating agents |
DK3786160T3 (da) | 2017-10-27 | 2022-08-22 | Boehringer Ingelheim Int | Pyridinderivater og terapeutiske anvendelser deraf som trpc6-inhibitorer |
WO2019111107A1 (en) * | 2017-12-05 | 2019-06-13 | Glaxosmithkline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
CN109928921A (zh) * | 2017-12-18 | 2019-06-25 | 成都华健未来科技有限公司 | Ido抑制剂 |
CN109956929B (zh) * | 2017-12-22 | 2023-09-19 | 上海迪诺医药科技有限公司 | 杂环衍生物、其制备方法、药物组合物及应用 |
CN109956937A (zh) * | 2017-12-22 | 2019-07-02 | 上海海雁医药科技有限公司 | N-(2-环己基乙基)甲酰胺衍生物、其制法与医药上的用途 |
WO2019120256A1 (zh) * | 2017-12-22 | 2019-06-27 | 上海迪诺医药科技有限公司 | 五元杂芳环衍生物、其药物组合物及应用 |
CN109574988B (zh) * | 2017-12-25 | 2022-01-25 | 成都海博锐药业有限公司 | 一种化合物及其用途 |
CA3084829A1 (en) | 2018-01-05 | 2019-07-11 | Dicerna Pharmaceuticals, Inc. | Reducing beta-catenin and ido expression to potentiate immunotherapy |
WO2019136112A1 (en) | 2018-01-05 | 2019-07-11 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
EP3737681A4 (en) * | 2018-01-10 | 2022-01-12 | Recurium IP Holdings, LLC | BENZAMIDE COMPOUNDS |
WO2019141095A1 (zh) * | 2018-01-19 | 2019-07-25 | 四川科伦博泰生物医药股份有限公司 | 脒类和胍类衍生物、其制备方法及其在医药上的应用 |
CN110066271B (zh) * | 2018-01-23 | 2023-04-07 | 上海迪诺医药科技有限公司 | 吡咯衍生物、其制备方法、药物组合物及应用 |
CN110066236B (zh) * | 2018-01-24 | 2023-03-24 | 上海迪诺医药科技有限公司 | 1h-吡咯衍生物、其制备方法、药物组合物及应用 |
CN110092750B (zh) * | 2018-01-29 | 2023-07-21 | 北京诺诚健华医药科技有限公司 | 五氟硫烷基取代的酰胺类化合物、其制备方法及其在医药学上的应用 |
WO2019154380A1 (zh) * | 2018-02-11 | 2019-08-15 | 南京明德新药研发股份有限公司 | 犬尿氨酸通路抑制剂 |
IL300572A (en) | 2018-02-13 | 2023-04-01 | Gilead Sciences Inc | PD–1/PD–L1 inhibitors |
CN110156656B (zh) * | 2018-02-13 | 2023-04-07 | 上海迪诺医药科技有限公司 | 五元杂芳环衍生物、其制备方法、药物组合物及应用 |
MX2020008984A (es) * | 2018-02-28 | 2020-12-09 | Dart Neuroscience Llc | Compuestos de ciclohexilo sustituido como inhibidores de nop. |
JP2021515767A (ja) | 2018-03-07 | 2021-06-24 | バイエル・アクチエンゲゼルシヤフト | Erk5阻害剤の同定及び使用 |
CN111630043B (zh) * | 2018-03-19 | 2022-02-15 | 四川科伦博泰生物医药股份有限公司 | 含环化合物、其制备方法及其在医药上的应用 |
CN110357813A (zh) * | 2018-04-09 | 2019-10-22 | 信达生物制药(苏州)有限公司 | 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途 |
JP7242702B2 (ja) | 2018-04-19 | 2023-03-20 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
CN110498769A (zh) * | 2018-05-17 | 2019-11-26 | 南京药捷安康生物科技有限公司 | Ido抑制剂与应用 |
CN110105275B (zh) * | 2018-05-28 | 2020-12-29 | 上海海雁医药科技有限公司 | 酰胺类衍生物、其制法与医药上的用途 |
US11098027B2 (en) * | 2018-07-06 | 2021-08-24 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
PT3820572T (pt) | 2018-07-13 | 2023-11-10 | Gilead Sciences Inc | Inibidores pd-1/pd-l1 |
WO2020018670A1 (en) * | 2018-07-17 | 2020-01-23 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
US20210355113A1 (en) | 2018-07-23 | 2021-11-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2020023355A1 (en) | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10959986B2 (en) | 2018-08-29 | 2021-03-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11253525B2 (en) | 2018-08-29 | 2022-02-22 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
CN110878013B (zh) * | 2019-12-13 | 2023-04-28 | 西安瑞联新材料股份有限公司 | (反,反)-4-乙烯基-4’-[(e)-1-丙烯基]-双环己烷的合成方法 |
US10980756B1 (en) | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
WO2021230710A1 (ko) * | 2020-05-15 | 2021-11-18 | (주)신테카바이오 | 신규 ido/tdo 억제제, 그의 항암 용도, 그의 항암 병용 요법 |
KR102653960B1 (ko) * | 2020-07-23 | 2024-04-03 | 의료법인 성광의료재단 | 암 치료를 위한 면역체크포인트 억제제의 병용 요법 |
EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
BR112023017582A2 (pt) | 2021-03-05 | 2023-12-05 | Univ Basel | Composições para o tratamento de doenças ou condições associadas ao ebv |
AU2022289728A1 (en) * | 2021-06-11 | 2023-11-16 | Neuronascent, Inc. | Methods and compositions for lipid formulation of lipophilic small molecule therapies of the heterocyclic type |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3169188B2 (ja) * | 1991-01-31 | 2001-05-21 | 杏林製薬株式会社 | カルバミン酸誘導体及びその製造方法 |
AU666040B2 (en) | 1992-10-28 | 1996-01-25 | Bayer Aktiengesellschaft | Substituted 1-H-3-aryl-pyrrolidine-2,4-dione derivatives |
DE4239151A1 (de) | 1992-11-20 | 1994-05-26 | Thomae Gmbh Dr K | N,N-Disubstituierte Arylcycloalkylamine, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung |
GB9411099D0 (en) | 1994-06-03 | 1994-07-27 | Wyeth John & Brother Ltd | Piperazine derivatives |
WO1999029852A1 (en) | 1997-12-05 | 1999-06-17 | Medical College Of Georgia Research Institute, Inc. | High-affinity tryptophan transporter |
CO5150225A1 (es) | 1999-03-19 | 2002-04-29 | Merck Sharp & Dohme | Derivados del tetrahidropirano y su uso como agentes terapeuticos |
AU5032400A (en) * | 1999-05-21 | 2000-12-12 | Wake Forest University | Sigma-1 ligands useful for determining the proliferative status of cancer cells |
US6291499B1 (en) * | 1999-10-29 | 2001-09-18 | Merck & Co., Inc. | 2-cyclohexyl benzimidazole NMDA/NR2B antagonists |
AU2001233044A1 (en) * | 2000-01-28 | 2001-08-07 | Akkadix Corporation | Methods for killing nematodes and nematode eggs using bis-amino-1,2,4-thiadiazoles |
US6677336B2 (en) | 2000-02-22 | 2004-01-13 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
WO2001092204A1 (en) | 2000-06-01 | 2001-12-06 | Warner-Lambert Company | Cyclohexylamine derivatives as subtype selective nmda receptor antagonists |
EP1296953A2 (en) * | 2000-06-23 | 2003-04-02 | Eli Lilly And Company | Methods and compounds for inhibiting mrp1 |
EP1317425B1 (en) * | 2000-09-11 | 2004-11-03 | Pfizer Products Inc. | Resorcinol derivatives |
AU2001284362A1 (en) * | 2000-09-21 | 2002-04-02 | Pfizer Products Inc. | Resorcinol derivatives |
EP1217000A1 (en) * | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
CA2476296C (en) * | 2002-03-13 | 2011-02-22 | Janssen Pharmaceutica N.V. | Amino-derivatives as inhibitors of histone deacetylase |
MY134200A (en) * | 2002-04-12 | 2007-11-30 | Kowa Co | Method for treating cancer |
US20040029887A1 (en) | 2002-05-23 | 2004-02-12 | Bhatia Pramila A. | Acetamides and benzamides that are useful in treating sexual dysfunction |
AU2003293006A1 (en) * | 2002-11-22 | 2004-06-18 | Japan Tobacco Inc. | Fused bicyclic nitrogen-containing heterocycles |
AU2003300902A1 (en) | 2002-12-13 | 2004-07-09 | Smithkline Beecham Corporation | Piperidine derivatives as CCR5 antagonists |
BRPI0407827B8 (pt) * | 2003-02-26 | 2021-05-25 | Sugen Inc | compostos de aminoeteroarila como inibidores de proteína cinase e respectivos usos |
JP2006521377A (ja) | 2003-03-27 | 2006-09-21 | ランケナー インスティテュート フォー メディカル リサーチ | 新型ido阻害剤とその使用方法 |
US7598287B2 (en) | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
US20050197371A1 (en) * | 2003-11-13 | 2005-09-08 | Ambit Biosciences Corporation | Urea derivatives as PDGFR modulators |
BRPI0507636A (pt) * | 2004-02-11 | 2007-07-10 | Pfizer | compostos, derivados terapêuticos de amida, composição farmacêutica, uso dos mesmos e combinação |
DE102004023507A1 (de) | 2004-05-10 | 2005-12-01 | Grünenthal GmbH | Substituierte Cyclohexylessigsäure-Derivate |
DE102004039789A1 (de) * | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
TW200720231A (en) * | 2005-04-21 | 2007-06-01 | Dainippon Sumitomo Pharma Co | An n-substituted phenylacetamide derivative and a pharmaceutical composition thereof |
EA026785B1 (ru) | 2005-05-10 | 2017-05-31 | Инсайт Холдингс Корпорейшн | Модуляторы индоламин 2,3-диоксигеназы и способы их применения |
WO2007044085A2 (en) * | 2005-05-19 | 2007-04-19 | Xenon Pharmaceuticals Inc. | Heteroaryl compounds and their uses as therapeutic agents |
US20070004763A1 (en) * | 2005-06-10 | 2007-01-04 | Nand Baindur | Aminoquinoline and aminoquinazoline kinase modulators |
KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
AU2006316605B2 (en) * | 2005-11-17 | 2012-04-26 | Osi Pharmaceuticals, Inc. | Fused bicyclic mTOR inhibitors |
WO2007082079A2 (en) * | 2006-01-12 | 2007-07-19 | The Scripps Research Institute | Piperidine amide derivatives as protein kinase inhibitors |
US20070203140A1 (en) | 2006-02-09 | 2007-08-30 | Combs Andrew P | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase |
EP1996193A2 (en) * | 2006-03-13 | 2008-12-03 | OSI Pharmaceuticals, Inc. | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
US20080039453A1 (en) | 2006-03-20 | 2008-02-14 | David Putman | Enantiomerically pure R-etifoxine, pharmaceutical compositions thereof and methods of their use |
WO2007137107A2 (en) * | 2006-05-19 | 2007-11-29 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
SI2032535T1 (sl) | 2006-06-01 | 2012-12-31 | Sanofi | Spirociklični nitrili kot proteazni inhibitorji |
US20080119491A1 (en) | 2006-09-19 | 2008-05-22 | Incyte Corporation | Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
JP2010509224A (ja) | 2006-11-06 | 2010-03-25 | ニューロジェン・コーポレーション | cis−シクロヘキシル置換ピリミジノン誘導体 |
CA2672373C (en) | 2006-12-19 | 2011-08-30 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
WO2008088540A2 (en) * | 2006-12-26 | 2008-07-24 | Amgen Inc. | N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases |
JP5405316B2 (ja) * | 2006-12-27 | 2014-02-05 | サノフイ | シクロアルキルアミン置換イソキノリン誘導体 |
WO2008133975A1 (en) * | 2007-04-26 | 2008-11-06 | Avalon Pharmaceuticals | Multi-ring compounds and uses thereof |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
US8436028B2 (en) * | 2007-06-20 | 2013-05-07 | Merck Sharp & Dohme Corp | CETP inhibitors derived from benzoxazole arylamides |
WO2009000085A1 (en) * | 2007-06-27 | 2008-12-31 | Painceptor Pharma Corporation | Quinoline and quinazoline derivatives useful as modulators of gated ion channels |
EP2178563A2 (en) * | 2007-07-06 | 2010-04-28 | OSI Pharmaceuticals, Inc. | Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2 |
WO2009009116A2 (en) | 2007-07-12 | 2009-01-15 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
CA2702950A1 (en) | 2007-10-16 | 2009-04-23 | Northeastern University | Methods and compounds for modulating cannabinoid activity |
CN110003123B (zh) * | 2008-03-18 | 2023-06-23 | 艾尼纳制药公司 | 用于治疗前列环素(pgi2)受体相关病症的pgi2受体调节剂 |
EP2260021B1 (de) * | 2008-03-27 | 2014-04-23 | Grünenthal GmbH | Substituierte 4-aminocyclohexan-derivate |
WO2009151800A1 (en) * | 2008-05-07 | 2009-12-17 | Merck & Co., Inc. | Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment |
CN104042611B (zh) | 2008-07-08 | 2019-05-14 | 因塞特控股公司 | 作为吲哚胺2,3-双加氧酶的抑制剂的1,2,5-噁二唑 |
US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
SG196798A1 (en) | 2008-12-09 | 2014-02-13 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
CA2740193A1 (en) | 2008-12-23 | 2010-07-01 | Abbott Laboratories | Anti-viral compounds |
WO2010094126A1 (en) * | 2009-02-23 | 2010-08-26 | Merck Frosst Canada Ltd. | Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
RU2646139C1 (ru) | 2009-09-03 | 2018-03-01 | Мерк Шарп И Доум Корп. | Анти-gitr-антитела |
CN102791738B (zh) | 2009-12-10 | 2015-10-07 | 霍夫曼-拉罗奇有限公司 | 优先结合人csf1r胞外域4的抗体及其用途 |
PL2542256T3 (pl) | 2010-03-04 | 2020-01-31 | Macrogenics, Inc. | Przeciwciała reaktywne wobec b7-h3, ich immunologicznie czynne fragmenty i ich zastosowania |
EP2542588A1 (en) | 2010-03-05 | 2013-01-09 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
EP2542587A1 (en) | 2010-03-05 | 2013-01-09 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
EP2563771B1 (en) | 2010-04-24 | 2015-11-25 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
EP3943154A1 (en) | 2010-05-04 | 2022-01-26 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
US8658603B2 (en) | 2010-06-16 | 2014-02-25 | The Regents Of The University Of Michigan | Compositions and methods for inducing an immune response |
SG10201506906VA (en) | 2010-09-09 | 2015-10-29 | Pfizer | 4-1bb binding molecules |
WO2012087699A1 (en) | 2010-12-23 | 2012-06-28 | Magna Powertrain Of America, Inc. | Controlled gerotor actuated pre-trans parallel hybrid |
ES2669310T3 (es) | 2011-04-20 | 2018-05-24 | Medimmune, Llc | Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1 |
US9586928B2 (en) * | 2011-05-16 | 2017-03-07 | The Scripps Research Institute | Modulators of the nuclear hormone receptor ROR |
JP5947897B2 (ja) * | 2011-09-22 | 2016-07-06 | メルク・シャープ・エンド・ドーム・ベー・フェー | N−ピペリジン−4−イル誘導体 |
TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ep2受體拮抗劑之新穎2h-吲唑 |
PT2785375T (pt) | 2011-11-28 | 2020-10-29 | Merck Patent Gmbh | Anticorpos anti-pd-l1 e usos destes |
WO2013086002A1 (en) * | 2011-12-05 | 2013-06-13 | Cellworks Research India Private Limited | Compositions, process of preparation of said compositions and method of treating cancer |
MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
KR20220162819A (ko) | 2012-05-11 | 2022-12-08 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
RS55500B1 (sr) * | 2012-06-26 | 2017-05-31 | Bayer Pharma AG | N-[4-(hinolin-4-iloksi)cikloheksil(metil)](hetero)arilkarboksamidi kao antagonisti androgenog receptora, njihova proizvodnja i upotreba kao medicinski produkti |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
WO2014007998A1 (en) * | 2012-07-06 | 2014-01-09 | The Regents Of The University Of California | SORAFENIB DERIVATIVES AS p21 INHIBITORS |
CN114984062A (zh) | 2012-08-30 | 2022-09-02 | 安姆根有限公司 | 使用单纯疱疹病毒和免疫检查点抑制剂治疗黑色素瘤的方法 |
CN104684582A (zh) | 2012-08-31 | 2015-06-03 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
KR20150128891A (ko) * | 2013-03-15 | 2015-11-18 | 브리스톨-마이어스 스큅 컴퍼니 | 인돌아민 2,3-디옥시게나제 (ido)의 억제제 |
US20160045556A1 (en) * | 2013-03-29 | 2016-02-18 | Biomed Valley Discoveries, Inc. | C. novyi for the treatment of solid tumors in non-human animals |
JP2017525753A (ja) | 2014-06-06 | 2017-09-07 | フレクサス・バイオサイエンシーズ・インコーポレイテッドFlexus Biosciences, Inc. | 免疫調節剤 |
GB201419579D0 (en) | 2014-11-03 | 2014-12-17 | Iomet Pharma Ltd | Pharmaceutical compound |
AR102537A1 (es) | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | Agentes inmunomoduladores |
UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
JP2017538678A (ja) | 2014-11-05 | 2017-12-28 | フレクサス・バイオサイエンシーズ・インコーポレイテッドFlexus Biosciences, Inc. | 免疫調節剤 |
-
2015
- 2015-11-04 AR ARP150103582A patent/AR102537A1/es unknown
- 2015-11-04 UY UY0001036391A patent/UY36391A/es unknown
- 2015-11-05 WO PCT/US2015/059316 patent/WO2016073774A2/en active Application Filing
- 2015-11-05 SG SG11201702827VA patent/SG11201702827VA/en unknown
- 2015-11-05 CA CA2964297A patent/CA2964297A1/en not_active Abandoned
- 2015-11-05 KR KR1020177015284A patent/KR102647639B1/ko active IP Right Grant
- 2015-11-05 US US15/524,092 patent/US20180325889A1/en not_active Abandoned
- 2015-11-05 EP EP15857810.4A patent/EP3215142B1/en active Active
- 2015-11-05 MA MA44549A patent/MA44549A1/fr unknown
- 2015-11-05 TW TW104136570A patent/TW201630866A/zh unknown
- 2015-11-05 MX MX2017005729A patent/MX2017005729A/es unknown
- 2015-11-05 PE PE2017000811A patent/PE20171623A1/es not_active Application Discontinuation
- 2015-11-05 MA MA40290A patent/MA40290A1/fr unknown
- 2015-11-05 AU AU2015342944A patent/AU2015342944A1/en not_active Abandoned
- 2015-11-05 US US14/933,879 patent/US9598422B2/en active Active
- 2015-11-05 BR BR112017007782A patent/BR112017007782A2/pt not_active IP Right Cessation
- 2015-11-05 CN CN201580060328.5A patent/CN106999450B/zh active Active
- 2015-11-05 ES ES15857810T patent/ES2867748T3/es active Active
- 2015-11-05 JP JP2017524423A patent/JP6762299B2/ja active Active
- 2015-11-05 TN TN2017000165A patent/TN2017000165A1/en unknown
- 2015-11-05 EA EA201790998A patent/EA201790998A1/ru unknown
-
2017
- 2017-02-01 US US15/422,118 patent/US10206893B2/en active Active
- 2017-04-03 PH PH12017500604A patent/PH12017500604A1/en unknown
- 2017-04-28 IL IL252010A patent/IL252010A0/en unknown
- 2017-05-05 CL CL2017001126A patent/CL2017001126A1/es unknown
- 2017-05-25 CO CONC2017/0005218A patent/CO2017005218A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017007782A2 (pt) | agentes imunorreguladores | |
BR112017008809A2 (pt) | agentes imunorreguladores | |
BR112016028255A2 (pt) | agentes imunorreguladores | |
PH12017500629A1 (en) | Immuniregulatory agents | |
CL2019001711A1 (es) | Composiciones y métodos para inhibir la acción de la arginasa. | |
HK1247922A1 (zh) | 用於治療癌症的吲哚胺2,3-雙加氧酶抑制劑 | |
BR112018013827A2 (pt) | moduladores de 5?-nucleotidase, ecto e uso dos mesmos | |
CL2018001358A1 (es) | Composiciones que comprenden cepas bacterianas | |
PH12015502028A1 (en) | Ido inhibitors | |
MX2018005600A (es) | Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello. | |
MX2016000295A (es) | Inhibidores de indoleamina 2,3-dioxigenasa (ido). | |
BR112017009671A2 (pt) | inibidores de ezh2 e usos destes | |
MX2016002075A (es) | Inhibidores de indolamina 2,3-dioxigenasa (ido). | |
MX2015017486A (es) | Inhibidores de indolamina 2,3-dioxigenasa (dio). | |
BR112017004704A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo | |
MX2015011374A (es) | Inhibidores de indolamina 2,3-dioxigenasa (ido). | |
MX2017015923A (es) | Inhibidores de indolamina-2,3-dioxigenasa (ido). | |
CL2016002779A1 (es) | Composición para el cuidado de la piel | |
BR112016018544A8 (pt) | Compostos ciclopropilaminas, composição farmacêutica que os compreende, seus usos no tratamento de câncer ou uma doença viral ou um beta-globinopatia e método de inibição de lsd1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |